Our Science
Overview
Through its differentiated ADC programs, NEOK aims to overcome the efficacy and safety limitations of conventional ADCs in the treatment of cancer.
Unleashing the Promise of Bispecific ADC Therapies
Our differentiation is rooted in our novel Topo-1-based platform that combines an intelligent choice of target antigens and antibody formats, with the latest advances in payload and conjugation technology. This enables us to develop bispecific formats which are fine-tuned for each target antigen pair.
​
The platform utilizes a proprietary, validated linker-payload technology (SYNtecan E™) that enables ADC generation with strong linker stability and superior biophysical properties. With regards to payload, exatecan has potential advantages over other approved Topoisomerase-1 (Topo-1) inhibitors including increased permeability and greater bystander effect, and lower risk of resistance (as exatecan is not an MDR1 substrate).
Enhanced Efficacy, Wider Therapeutic Margin, Broad Patient Benefit
This dual-targeting strategy has the potential to target a wider range of tumors, overcome drug resistance, increase internalization rates and cell killing, and improve the safety profile by increasing selectivity and reducing off-tumor toxicity.
